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Abstract: Bisphosphonates, used to treat diseases exhibiting increased osteoclast activity, reduce longitudinal bone 
growth through an as yet undefined mechanism. Pamidronate, an aminobisphosphonate, was given weekly to mice at 0, 
1.25, or 2.50 mg/kg/wk beginning at 4 weeks of age. At 12 weeks of age, humeral length, growth plate area, regional 
chondrocyte cell numbers, chondrocyte apoptosis, TRAP stained osteoclast number, and osteoclast function assessed by 
cathepsin K immunohistochemistry were quantified. Humeral length was decreased in pamidronate treated mice compared 
to vehicle control mice, and correlated with greater growth plate areas reflecting greater proliferative and hypertrophic 
chondrocyte cell numbers with fewer hypertrophic cells undergoing apoptosis. Pamidronate treatment increased TRAP 
stained osteoclast numbers yet decreased cathepsin K indicating that pamidronate repressed osteoclast maturation and 
function. The data suggest that long term cyclic pamidronate treatment impairs bone growth by inhibition of osteoclast 
maturation thereby reducing cartilage-to-bone turnover within the growth plate. 
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INTRODUCTION 
  One preferred treatment for human diseases characterized 
by increased osteoclast activity, such as osteoporosis and 
osteogenesis imperfecta, is bisphosphonate therapy [1]. 
Bisphosphonates primarily affect bone remodeling through 
inhibition of the osteoclast by reducing osteoclast formation 
and chemotaxis, or increasing osteoclast apoptosis [2-4], 
although increased osteoblast growth factor expression and 
lowered articular chondrocyte apoptosis also have been 
documented [5]. While inhibition of bone resorption is desir-
able for treating some disease, bone resorption is critical for 
bone development and skeletal maintenance. Normal bone 
elongation requires cartilage-to-bone conversion at en-
dochondral growth plates. Treatment with bisphosphonates 
during the growth period could inhibit the normal osteoclast 
and chondroclast function necessary for that cartilage-to-
bone turnover, thereby impairing linear bone growth. Studies 
employing bisphosphonates have reported decreased bone 
formation rate and increased accumulation of mineralized 
growth plate tissue in the metaphyseal secondary spongiosa 
[6]. In addition, abnormal bone remodeling and accumula-
tion of mineralized cartilage remnants have been reported for 
individuals treated with bisphosphonates during growth [7-
9]. 
  Very little is known about the effects of bisphosphonates 
on cells within the active growth plate and whether pro-
longed inhibition of osteoclasts adversely affects bone 
growth when bisphosphonates are used during the growth   
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phase on into adulthood. In this study we evaluated the effect 
of long term cyclic pamidronate treatment, a clinically rele-
vant bisphosphonate, on bone elongation parameters includ-
ing length, growth plate area, chondrocyte apoptosis, osteo-
clast numbers, and osteoclast function in a mouse model in 
an effort to understand how bisphosphonate inhibition of 
osteoclasts influences bone elongation at the growth plate. 
MATERIALS AND METHODOLOGY 
  Wild type mice were produced by breeding heterozygous 
B6C3Fe-a/a-Cola2oim/+ hybrid oim/wt obtained from Jack-
son Laboratories (Bar Harbor, ME). All mice were housed at 
constant temperature (70 ± 2°F), fed Purina mouse diet for-
mula 5008 (Purina, St. Louis, MO) and provided tap water 
ad lib. Wild type mice used in this study were genotypically 
confirmed [10], weaned at 3 wks of age, and housed accord-
ing to sex. At 4 wks of age, mice were assigned randomly to 
experimental groups based on sex (male and female) and 
pamidronate dose (vehicle control (0 mg/kg/wk), low (1.25 
mg/kg/wk), and high (2.50 mg/kg/wk)) with 9 to 10 animals 
per group. Doses were selected to bracket pamidronate doses 
therapeutically administered to children [11-13] and that 
used in previous mouse studies [14]. Beginning at 4 wks of 
age (±2 days), mice were given weekly intraperitoneal injec-
tions of pamidronate (Aredia
TM, Novartis Pharmaceuticals, 
East Hanover, NJ) reconstituted in phosphate-buffered saline 
(PBS) or PBS vehicle alone. At 12 wks of age, mice were 
killed by CO2 narcosis and their humeral bones were col-
lected. All animal procedures were approved by the Univer-
sity of California Davis Institutional Animal Care and Use 
Committee. 
  Bilateral humeri were dissected and length measured 
from the proximal end of the humeral head to the distal   
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aspect of the humeral medial epicondyle. Bones were pre-
pared for histology as previously described [7] except that 
decalcification was done in 0.5 M EDTA for at least 3 wks 
[15] after which the bones were individually rinsed for 72 h 
under running water and stored in 70% ethanol for a mini-
mum of 24 h. Mid-saggital longitudinal sections (6 m) in 
the transverse plane were taken at approximately the same 
depth to permit direct comparisons between bones. Sections 
were stained with hematoxylin and eosin, and growth plate 
area measured as the area encompassing the entire growth 
plate from germinal cell layer to the last intact transverse 
cartilage septa of the hypertrophic region. Growth plate 
height was taken from the germinal layer to the last intact 
transverse cartilage septa of the hypertrophic chondrocyte 
layer at three locations (medial, mid, and lateral aspects) 
within the growth plate. 
  The effect of pamidronate on cell turnover was assessed 
by TUNEL (Terminal-transferase dUTP Nick End labeling) 
staining for apoptotic chondrocytes (DeadEnd
TM Colorimet-
ric system for tissue sections, Promega, Madison WI). Left 
humeral transverse sections were taken from five animals for 
each pamidronate dose. Each slide contained three consecu-
tive slices of bone tissue from the mid-sagittal location of the 
proximal physis of the humerus again maintaining a constant 
depth of sectioning to allow for direct comparisons. Sections 
were counterstained with 0.1% methyl green. Apoptotic cells 
were identified as having a dark brown staining nucleus and 
no staining of apoptotic cells was detected in the negative 
control slides. On each slide, apoptotic cells were counted 
for each of the three consecutive tissue sections. Normal 
non-staining cells also were counted to obtain an overview 
of the relative proportion of apoptosis within the growth 
plate for each pamidronate dose. Additionally, proportional 
apoptotic cell counts were taken within the proliferative and 
hypertrophic regions of the growth plate region of each tis-
sue section in order to assess regional differences in chon-
drocyte apoptosis. For all growth plate parameters measured, 
males and females were not significantly different, therefore, 
females were used for TUNEL analysis and males were used 
for cathepsin K immunostaining. 
  Left humeral transverse sections from three mice for each 
sex by pamidronate dose were rehydrated, then immersed 
overnight in a reactivation buffer (0.07 M Tris, 0.06 M hydro-
chloric acid, pH 9.0) and TRAP (tartrate resistant acid phos-
phatase) stained according to previous studies [16]. Following 
TRAP staining, slides were rinsed and counterstained with 1% 
methyl green. TRAP positive osteoclasts were counted to 
quantify the number of osteoclasts within the metaphyseal 
region directly below the growth plate on three consecutive 
bone sections. Total osteoclast counts were taken using an 
ocular eyepiece grid at a magnification of 400X; the entire 
grid area (0.0004 mm2) was used and included the total area at 
the chondro-osseous junction of the growth plate and extended 
0.02 mm distally and 0.02 mm medial-laterally. In addition, 
surface area of calcified cartilage and mineralized bone were 
taken within the same grid area to account for osteoclast num-
ber per surface area and to correlate differences in osteoclast 
number with potential changes in surface area due to pamidro-
nate dose effect. 
  Osteoclast function was assessed by cathepsin K staining. 
Left humeral transverse sections each containing three con-
secutive slices of bone tissue from the mid-sagittal section of 
the humeral bone from three males of each pamidronate dose 
were immunostained for cathepsin K using published meth-
odologies [16]. Briefly, each tissue section was deparaf-
finized and rehydrated in PBS. Pretreatments included anti-
gen retrieval in a 10 mM citrate buffer for 20 min at 55-
60°C. The cathepsin K primary antibody (Santa Cruz Bio-
technology Inc., Santa Cruz, CA) was used at a 1:100 dilu-
tion per sample. Antibody detection was done according to 
manufacturer’s directions (Vectastain ABC kit, Vector Labo-
ratories, Burlingame, CA). Negative control slides were pre-
pared by excluding the primary antibody but retaining all the 
other steps. Internal positive controls were achieved through 
cathepsin K staining of terminal hypertrophic cells [17]. Sec-
tions were counterstained with 0.1% methyl green. 
  The effects of pamidronate treatment on humeral length, 
growth plate area, and height were analyzed using least 
square means analysis of variance that included sex and dose 
treated as fixed effects (PROC GLM, SAS version 6.07; 
SAS Institute Inc., Cary, NC). Sex effects were only signifi-
cant (p < 0.05) for bone length. Within an individual, bone 
lengths were not significantly different between the right and 
left sides (p > 0.2) so right and left bone length values were 
averaged for each animal. Sex effects were not significant (p 
> 0.2) for all growth plate measurements and cellular evalua-
tion, therefore data from the two sexes were pooled. For all 
analyses, significance was defined as p < 0.05. Post hoc 
analyses were done using a Bonferroni adjustment. 
  Apoptotic cell proportions for the overall growth plate 
and its regions were analyzed using least square means 
analysis of variance (PROC MIXED, SAS) with replicate 
sections for each animal treated as nested values within each 
pamidronate dose. The effects of pamidronate treatment on 
number of TRAP stained osteoclast cells and calcified carti-
lage and bone surface area per grid were analyzed using least 
square means analysis of variance with dose and sex treated 
as fixed effects (PROC MIXED, SAS) and replicate sections 
for each animal treated as nested values within each sex and 
dose. For TRAP analysis, both sexes were combined for 
analysis because sex effects did not differ statistically (p > 
0.2). 
RESULTS 
  For humeral bone length, sex was significant (p < 0.01) 
with males having a longer humerus than females. Bone 
length was diminished 3% with pamidronate treatment for 
both males and females (p < 0.05) compared to vehicle 
treated control humeri (Table 1). Growth plate area and 
height were affected by pamidronate dose while sex (p > 0.2) 
was not significant therefore sexes were combined for fur-
ther growth plate dimensional analysis. Pamidronate treat-
ment was associated with a larger growth plate area: the high 
dose treated mice had a 20% increase (p < 0.005) when 
compared to vehicle treated control mice and the low dose 
increase was intermediate at 10% (Table 1). The enlarged 
growth plate area was predominantly due to greater growth 
plate height in pamidronate treated mice: a 57% and 68% 
increase for low and high doses, respectively, compared to 
vehicle treated mice. 
  Growth plate chondrocyte apoptosis and zone cell num-
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area and height observed with pamidronate treatment were 
associated with a dose-dependent increase in total number of 
growth plate chondrocytes and a lower proportion of total 
apoptotic growth plate chondrocytes (Table 1). The low pa-
midronate dose did not significantly change total prolifera-
tive cell numbers whereas proliferative chondrocyte number 
was increased with the high dose of pamidronate. Hypertro-
phic chondrocyte numbers displayed a dose-dependent in-
crease with the highest pamidronate dose increasing hyper-
trophic cells by 23% relative to vehicle control treated (p < 
0.03). The total percentage of apoptotic chondrocytes within 
the growth plate was significantly lower (~50% decrease) 
with pamidronate treatment (p < 0.001). 
  The number of TRAP stained osteoclasts expressed as 
number per unit of bone area was increased with both pa-
midronate doses compared to vehicle treated control mice. 
Greater osteoclast numbers were seen primarily within the 
metaphysic upon whole bone microscopic observation. Os-
teoclast numbers were higher with pamidronate treatment 
although immunohistochemical staining with cathepsin K 
indicated the activity of those osteoclasts was diminished 
(Fig.  1). Osteoclast staining for cathepsin K was virtually 
Table 1.  Pamidronate Effects on Humerus Length, Growth Plate (G.P.) Measurements, and Osteoclast Numbers in Mice 
 
  Control   Low   High   SEM  p Value 
Female Humerus Length, mm  12.29
a  
(10) 
11.92
b  
(10) 
11.97
b  
(10)  0.09 0.03 
Male Humerus Length, mm  12.56
a  
(10) 
12.15
b  
(10) 
12.12
b  
(10) 
0.08 0.009 
G. P. Area, mm
2  0.2663
a  
(10) 
0.3067
ab  
(10) 
0.3588
b  
(10) 
0.019 0.003 
G. P. Height, mm  0.0120
a  
(10) 
0.0188
b  
(10) 
0.0197
b 
(10)  0.001 0.001 
TRAP Osteoclasts Per mm
2 bone  3
a  
(5) 
6
b  
(5) 
6
b  
(5) 
0.6 0.01 
Proliferative Cell Total  336
a 
(5) 
359
a 
(5) 
421
b 
(5)  10 0.001 
Hypertrophic Cell Total  235
a 
(5) 
276
ab 
(5) 
290
b 
(5) 
15 0.03 
G.P. Cells Total  658
a 
(5) 
729
ab 
(5) 
804
b 
(5) 
17 0.001 
Proliferative Apoptotsis (%)  1.7
 
(5) 
1.9
 
(5) 
1.9
 
(5)  0.3 0.60 
Hypertrophic Apoptosis (%)  11.8
a 
(5) 
4.2
b 
(5) 
2.5
c 
(5) 
0.5 0.03 
Total G. P. Apoptosis (%)  5.7
a 
(5) 
3.4
b 
(5) 
2.6
b 
(5)  0.3 0.001 
Dose of pamidronate (vehicle control (0 mg/kg/wk), low (1.25mg/kg/wk), or high (2.50 mg/kg/wk) given for 8 wks and evaluated at 12 wks of age. Values are expressed as least 
square means ± standard error of the means, number of animals (n) is listed below means. Means having different superscripts within each measured parameter are significantly 
different. 
 
Fig. (1). Cathepsin K immunostaining of osteoclasts in growth plate sections from pamidronate treated mice. All sections demonstrated stain-
ing in hypertrophic cells which served as an internal positive control. Arrows depict stained osteoclasts lining the trabecular bone in the distal 
aspect of the proximal metaphysis below the chondro-osseous junction, though not all positively stained osteoclasts are indicated. Magnifica-
tion is 200X unless noted. (A) vehicle control dose treated male with cathepsin K stained osteoclasts, inset photo illustrates an osteoclast 
stained positive for cathepsin K (400X); (B) high pamidronate dose male lacking cathepsin K staining, inset photo (400X) illustrates the lack 
of cathepsin K staining in osteoclasts at the distal aspect of the proximal metaphysis relative to that depicted in (A) and (C) negative control 
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absent in the high dose pamidronate treated mice compared 
to vehicle treated control mice. To verify that greater osteo-
clast numbers were not due simply to changes in mineralized 
surface area available, surface areas were quantified. There 
were no significant differences in the measured metaphyseal 
mineralized surface area for sex (p > 0.4) or dose (p > 0.1) 
(data not shown). 
DISCUSSION 
  Bisphosphonates, particularly pamidronate, are used to 
increase bone mineral density, decrease fractures and bone 
pain and thus improve the quality of life for patients with 
elevated bone resorption such as seen in many osteogenesis 
imperfecta patients as well as postmenopausal osteoporosis. 
Improved mechanical properties and decreased bone pain 
with cyclic pamidronate dosing confirms the role of long 
term cyclic pamidronate as a palliative treatment [18], yet 
the effect of bisphosphonate inhibition of osteoclasts on 
growth plate function is not well defined. In the present 
study, humoral length was decreased in response to pa-
midronate, an expected response since alendronate, another 
bisphosphonate used in clinical trials for osteogenesis imper-
fecta, showed similar changes on bone length [7]. While 
alendronate is considered more potent than pamidronate [1], 
both bisphosphonates elicited similar changes to bone 
growth indicating both bisphosphonates have comparable 
biological effects on the growth plate. 
  While bisphosphonate doses cannot be directly compared 
between mice and children, correlating human height curves 
at the 50th percentile suggests that each week of pamidronate 
treatment in these mice was roughly equivalent to 0.5-1 year 
of a child receiving treatment during the growth phase [19]. 
Dosing schemes for children treated with intravenous pa-
midronate have ranged from 8 mg/kg/yr to 18 mg/kg/yr [11-
12] with higher pamidronate doses (114 mg/kg/yr) inducing 
osteopetrosis [13]. In the present study, the treatment period 
encompassed roughly 60% of the mouse humerus growth 
phase [20] and thus, the weekly doses used in this study were 
lower than the yearly dosages used in children yet still im-
paired bone elongation in the mice. 
  Chondrocyte cell turnover from resting to proliferative to 
hypertrophic and extracellular matrix deposition at en-
dochondral growth plates accounts for the majority of linear 
bone growth. Treatment with pamidronate inhibited apopto-
sis throughout the growth plate indicating that the bisphos-
phonate either directly disrupts normal cellular progression 
within the growth plate or does so indirectly through osteo-
clast inhibition resulting in reduced turnover at the chondro-
osseous junction. Hypertrophic chondrocytes must undergo 
apoptosis for normal bone elongation; this apoptosis occurs 
either by pre-programming or by induction by factors ac-
companying the invading metaphyseal vasculature [21, 22]. 
Although bisphosphonates target bone in general, they do 
concentrate in the metaphysis with very dense uptake in the 
region of mineralized cartilage just below the growth plate 
[23]. This would physically position the compound to affect 
hypertrophic and osteoclast cells, both critical to turnover at 
the chondro-osseus junction. 
  In bone, bisphosphonates have a direct inhibitory effect 
on osteoclast function and morphology [4, 24]. The in-
creased osteoclast numbers with reduced functional activity 
at the growth plate corroborates those findings. Reduction of 
osteoclast mediated metaphyseal vessel invasion would re-
strict the delivery of pro-apoptotic signals to the hypertro-
phic layer decreasing hypertrophic cell turnover. Mature 
osteoclasts capable of resorption secrete cathepsin K into the 
resorption lacuna [25]. Reduced cathepsin K staining indi-
cates an arrest of osteoclast initiation of resorption. Thus, the 
increase in osteoclasts observed in the present study in re-
sponse to pamidronate treatment may have been due to 1) 
decreased osteoclast apoptosis or 2) an increase in osteoclast 
numbers needed to sustain the basic multicellular unit 
(BMU) equilibrium [26] but that fail to achieve full osteo-
clastic maturation and resorptive capacity. Previous studies 
[2] report an increase in apoptosis for osteoclasts exposed to 
bisphosphonates suggesting that the increased osteoclast 
numbers observed in the present study were due to increased 
recruitment of osteoclast formation with inhibition of their 
full maturation. 
  Bisphosphonates also inhibit collagenase-3 expression, 
an enzyme essential for endochondral bone development 
[27]. Many studies demonstrate a direct role for collagen 
degradation in activation of osteoclasts and any reduction in 
collagenase-3 would result in impaired bone resorption (re-
viewed in [27]) contributing to the changes observed in the 
present study. Further, bisphosphonates could have reduced 
the action of chondroclasts, resorptive cells active at the zone 
of vascular invasion [28]. Although chondroclasts and osteo-
clasts were not individually counted, the number of TRAP 
positive cells was determined from the last intact hypertro-
phic cell into the primary spongiosa. Thus, any TRAP posi-
tive chondroclasts also would have been included in the pre-
sent data. It is likely that pamidronate would reduce the ac-
tion of chondroclasts in a manner similar to that proposed for 
the osteoclast. 
  The action of bisphosphonates on bone is thought to re-
flect its action on osteoclasts but other cell types (os-
teoblasts, tumor cells, monocytes) are known to respond to 
bisphosphonates [29]. Inhibition of bone growth by bisphos-
phonates likely reflects an action on multiple cell types. 
Aminobisphosphonates can inhibit the prenylation of GTP 
associated proteins Ras, Rac, and Rho [24, 30], factors vital 
to the signaling pathways that regulate osteoclast, osteoblast, 
and chondrocyte function. The GTP associated proteins, 
Rac1 and Rho, antagonistically regulate chondrocyte prolif-
eration, hypertrophy, and apoptosis in much the same man-
ner as they antagonistically act upon osteoclast formation, 
function, and motility [31]. Thus, in addition to the well-
known osteoclast effects of bisphosphonates there may also 
be a direct effect on the chondrocytes within the growth 
plate. In this study, it is possible that the increase in prolif-
erative and hypertrophic chondrocyte numbers seen with 
pamidronate treatment could be due to direct effects of pa-
midronate on signaling of GTP associated proteins involved 
in chondrocyte proliferation and or direct inhibitory effects 
on apoptosis signaling of chondrocytes due to the chondro-
protective effects of bisphosphonates [32]. 
CONCLUSIONS 
  This study showed that pamidronate in low and high 
doses over the majority of the growth phase reduced long 
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chondrocyte apoptosis, and growth plate chondrocyte num-
bers in conjunction with inhibition of multinucleated osteo-
clast activity. The bisphosphonate inhibited growth by de-
creasing chondrocyte turnover via inhibition of apoptosis at 
the hypertrophic layer along with bisphosphonate inhibition 
of multinucleated osteoclast activity. The inhibition of osteo-
clast activity may have reduced vessel invasion at the chon-
dro-osseous junction thereby exacerbating the growth inhibi-
tory effect of pamidronate by inhibiting invading vascular 
apoptotic signals. While this study demonstrated direct ef-
fects of bisphosphonates on growth plate function, the bene-
ficial effects of increased bone density and lowered fracture 
incidence in particular clinical conditions outweigh reduced 
growth plate activity. 
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